Max Hodak, a co‑founder of Neuralink who now runs a start‑up called Science, has described a string of clinical and conceptual advances that he says mark the beginning of a new, fast‑moving phase for brain‑computer interfaces (BCI). In a recent interview Hodak highlighted a retinal implant developed by Science — Prima — which he says has restored light perception and formed coherent visual images in more than 40 blind patients. That device, he added, has produced results in a multicentre clinical trial and the findings have been published in the New England Journal of Medicine, lending the claim peer‑reviewed weight.
Prima’s technical approach is straightforward and surgical rather than speculative. A two‑millimetre by two‑millimetre silicon chip is implanted beneath the retina and functions like a tiny solar‑cell array. Patients wear specialised glasses whose camera and laser projector send patterned light onto the implant; the microcells absorb that light and stimulate the retinal tissue above, bypassing dead photoreceptors and restoring a form of vision. The trial — conducted across 17 European centres and aimed at diseases in which photoreceptors are lost, such as age‑related macular degeneration and retinitis pigmentosa — reportedly produced substantial gains for some participants, with a number able to read letters on a vision chart.
Hodak used the clinical news as a springboard for a broader redefinition of BCI. He frames the nervous system as a set of compact information “cables” — the cranial nerves and spinal nerves — and calls neural spikes the brain’s API. From that standpoint, BCIs are simply engineered interfaces that decode and encode signals across those APIs. He argued that neural decoding and the internal representations of contemporary artificial‑intelligence models are converging: the latent spaces of machine models resemble the brain’s internal representations, making AI both a tool for BCI design and a beneficiary of neuroscientific insight.
Beyond stimulation and decoding, Hodak sketched more speculative engineering: so‑called biohybrid neural implants. Science is exploring implants that house stem‑cell‑derived neurons intended to grow and interconnect with host brain tissue, shielded from immune attack by low‑immunogenic coatings. The aim would be to create high‑bandwidth, living neural conduits — a neural equivalent of an internet connection — that could, in his words, enable forms of direct human‑machine coupling rarely seen outside science fiction.
Those futuristic projections extend to philosophical and sociopolitical claims. Hodak introduced the term "consciousness machines" and argued that only by building high‑bandwidth, experiential links to brains can researchers probe the physical basis of consciousness. He also made an attention‑grabbing longevity claim: he believes the first humans who might live to 1,000 years are already born, and that the uptake path for BCI will travel from restoring lost function, to treating age‑related decline, to elective enhancement that changes risk–benefit calculations and public acceptance.
The interview mixes demonstrable clinical progress with long‑shot extrapolation. Prima’s NEJM publication is a meaningful clinical milestone: a sensory prosthesis that moves beyond crude flashes to coherent percepts would be a technical and regulatory advance. But many of Hodak’s other propositions — growing integrated neural tissue inside implants, reliably hiding grafts from immune surveillance, or engineering machines that bear consciousness — confront substantial, unanswered scientific and ethical questions. Integration, longevity, immune reaction, tumor risk, signal fidelity and interpretability, and reversibility are all active challenges in neurotechnology research.
Hodak’s argument also has geopolitical resonance. States and private actors are racing to translate BCI into medical, commercial and potentially military capabilities. China, for example, is pushing provincial clusters and funding for BCI development, signalling that the field will not be confined to Silicon Valley. That raises familiar policy dilemmas: how to balance clinical access against safety, how to govern cognitive augmentation, and how to prevent unequal access from exacerbating social divides.
In short, the Science/Prima story is important because it shows BCIs moving from laboratory curiosities to regulated clinical interventions with measurable patient benefit. But the leap from prosthetic vision to biohybrid consciousness machines and millennial lifespans is vast. Hodak’s rhetoric captures a high‑stakes vision of the future that will spur investment and debate; converting that vision into reliable, safe technologies will require sustained, multidisciplinary work and robust oversight.